INTRODUCTION {#s1}
============

SLC12A proteins are transmembrane proteins mediating the electroneutral transport of cations such as Na^+^ and K^+^, together with Cl^−^ in and out of cells ([@DELPIREMCS001289C37]; [@DELPIREMCS001289C49]). They play fundamental roles in a variety of physiological settings. SLC12A transporters participate in epithelial ion transport, modulate inhibitory synaptic transmission, and maintain and regulate cell volume ([@DELPIREMCS001289C27]; [@DELPIREMCS001289C39]; [@DELPIREMCS001289C31]). Human mutations in two Na^+^-independent K^+^--Cl^−^ cotransporters KCC2 and KCC3 are involved in generalized idiopathic epilepsy (OMIM \#616685) ([@DELPIREMCS001289C30]), early infantile epileptic encephalopathy (OMIM \#616645) ([@DELPIREMCS001289C55]), and peripheral nerve degeneration (OMIM \#218000) ([@DELPIREMCS001289C29]; [@DELPIREMCS001289C62]; [@DELPIREMCS001289C4]; [@DELPIREMCS001289C58]; [@DELPIREMCS001289C32]), respectively. Mouse models of these disorders recapitulate the main aspects of the phenotypes ([@DELPIREMCS001289C29]; [@DELPIREMCS001289C28]; [@DELPIREMCS001289C62]; [@DELPIREMCS001289C4]; [@DELPIREMCS001289C32]). Human mutations in two of the three Na^+^-dependent cation Cl^−^ cotransporters are responsible for well-characterized salt-wasting disorders: Bartter syndrome (OMIM \#607364) for NKCC2 ([@DELPIREMCS001289C52]) and Gitelman syndrome (OMIM \#263800) for NCC ([@DELPIREMCS001289C53]), respectively. Mouse models accurately phenocopy these two disorders ([@DELPIREMCS001289C50]; [@DELPIREMCS001289C57]). One cation-chloride cotransporter that has eluded the list of cotransporters with human mutations is the ubiquitous Na-K-2Cl cotransporter-1 or NKCC1. NKCC1, like its family of transporters, plays a role in epithelial ion transport ([@DELPIREMCS001289C43]; [@DELPIREMCS001289C5]; [@DELPIREMCS001289C35]; [@DELPIREMCS001289C60]), modulates inhibitory synaptic transmission ([@DELPIREMCS001289C56]; [@DELPIREMCS001289C18]), and maintains and regulates cell volume ([@DELPIREMCS001289C64]; [@DELPIREMCS001289C8]; [@DELPIREMCS001289C40]). Accordingly, the knockout mouse exhibits multiple phenotypes that include sensorineural deafness ([@DELPIREMCS001289C14]; [@DELPIREMCS001289C17]; [@DELPIREMCS001289C21]), male infertility ([@DELPIREMCS001289C44]), intestinal transit deficiency ([@DELPIREMCS001289C21]; [@DELPIREMCS001289C63]; [@DELPIREMCS001289C6]), deficit in saliva secretion ([@DELPIREMCS001289C19]), and a pain perception phenotype ([@DELPIREMCS001289C56]; [@DELPIREMCS001289C36]; [@DELPIREMCS001289C26]). The absence of any report of human mutations in NKCC1 is puzzling and could indicate either complete intolerance to genetic variations (individuals selected out during gestation) or a large tolerance to genetic variations (many individuals carrying mutations without significant deleterious phenotypes). In this article, we report the case of a unique patient that carries a de novo truncation mutation in NKCC1.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

In 2010, an 8-yr-old female presented to the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP) with a complex syndrome including obstructive apnea, episodes of vomiting and dehydration, ketotic hypoglycemia with illness, decrease energy and fatigue, exercise intolerance, dilated cardiomyopathy (left ventricle dilation), and seizure-like episodes. Her prenatal/natal history was unremarkable: The maternal age was 35 yr (four pregnancies, four births), and the paternal age was 33 yr. Maternal weight gain was 25 lb, and fetal movements were described as normal. She was delivered after 38-wk gestation via Cesarean section (8 lb, 12 oz, 21 in, Apgar scores of 8 and 9) and discharged at 5 d following a mild jaundice. All developmental milestones were reached on time. Her symptoms began at ∼6 mo of age. Extensive diagnostic and therapeutic medical interventions included a liver and muscle biopsy (Supplemental Table S5), and a gastric tube placed help manage and/or abort metabolic decompensations. Her dietary course was particularly challenging. Dietary intolerance prompted a progression from a high-protein formula to a free amino acid formula, and finally to total parenteral nutrition (TPN) at an age of 11 yr. Her weight is currently 40 kg (41st percentile). She is receiving 75 mL/kg/d of TPN with intermittent phosphate and essential fatty acid supplementation. Orthostatic intolerance is treated with intermittent 20 mL/kg i.v. fluid supplements. Heart rate and blood pressure lability are treated with daily midodrine, propranolol, and florinef (per jejunal tube). Respiratory support includes overnight bilevel positive airway pressure (BiPAP) for apnea and CO~2~ retention. Cognitive function is normal. She attends school and shows normal locomotion and posture. Her vision, hearing, taste, and smell are seemingly normal, but she suffers from chronic pain treated with scheduled i.v. fentanyl. Chronic nausea is treated with pantoprazole, granisetron, diphenhydramine, and ondansetron. Episodic anxiety is treated with diazepam.

Genomic Analysis {#s2b}
----------------

To identify potentially pathogenic DNA sequence variants coding mutations in the patient\'s genome, exome sequencing was performed on the patient, both unaffected parents, and three unaffected siblings. The genome fraction coverage data are provided in Supplemental Figure S1 and Supplemental Tables S1--S4. Variants that were rare, nonsynonymous, start-gain/loss, stop-gain/loss, frameshift, canonical splice site variants, or intronic variants (±20 bp) that were consistent with homozygous recessive, compound heterozygous, X-linked, or de novo dominant disease models were retained. Variant prioritization included factors such as population frequency, effect on amino acid coding, segregation, and predicted pathogenicity ([Table 1](#DELPIREMCS001289TB1){ref-type="table"}). No clear pathogenic variants were found in known disease-causing genes. However, four mutations were prioritized for further analysis ([Table 1](#DELPIREMCS001289TB1){ref-type="table"}, top four rows). The patient is compound heterozygous for variants in *PCNT* (pericentrin). PCNT is an integral component of the pericentriolar material that interacts with the microtubule nucleation component γ-tubulin. PCNT may be critical to the normal function of the centrosomes, cytoskeleton, and cell-cycle progression ([@DELPIREMCS001289C22]). Homozygous or compound heterozygous variants in PCNT have been reported in patients with microcephalic osteodysplastic primordial dwarfism type 2 (MOPD2, OMIM 210720) ([@DELPIREMCS001289C61]), making it unlikely that these heterozygous mutations account for the patient\'s disease. Two de novo mutations were also identified in the patient. First, we identified a missense mutation in *FMN2*, the gene encoding formin 2. FMN2 plays a role in cytoskeletal organization and the establishment of cell polarity ([@DELPIREMCS001289C38]). Truncating variants in this gene were previously reported in patients with autosomal recessive mental retardation-47 (OMIM \#616193) ([@DELPIREMCS001289C38]), and there is no clear association to the clinical features of our patient. Second, a frameshift truncating variant in *SLC12A2*, the gene encoding the Na-K-2Cl cotransporter-1, was identified. As seen in Supplemental Figure S2, neither parents nor siblings carried the mutation, indicating that it originated de novo in germ cells. Among other processes, NKCC1 is involved in transcellular movement of chloride across both secretory and absorptive epithelia ([@DELPIREMCS001289C45]). The widespread expression and critical functionality of NKCC1, the deleterious nature, novelty, mode of inheritance, and high in silico deleteriousness score of the variant made the NKCC1 mutation the highest priority.

###### 

Total list of variants

  Gene             Chr Pos                         HGVS cDNA                                HGVS protein    CADD          ExAC All          ExAC European
  ---------------- ------------------------------- ---------------------------------------- --------------- ------- -------------------- -------------------
  *SLC12A2*        Chr5:127514355ATGTCTGGTGGC\>A   NM_001046.2: c.3076_3086delGTCTGGTGGCT   p.V1026Ffs\*2   36                           
  *FMN2*           Chr1:240371852C\>T              NM_020066.4:c.3740C\>T                   p.P1247L        22.6                         
  *PCNT*           Chr21:47817316G\>A              NM_006031.5:c.4354G\>A                   p.G1452R        23.8     384/121282 = 0.003   166/66660 = 0.002
  *PCNT*           Chr21:47852019C\>T              NM_006031.5:c.8641C\>T                   p.R2881W        25.2        1/120192 = 0         1/66000 = 0
  *RYR1*           Chr19:39057626G\>C              NM_000540.2:c.13513G\>C                  p.D4505H        23.4     281/46430 = 0.006    234/24010 = 0.01
  *RYR1*           Chr19:39016132G\>A              NM_000540.2:c.10616G\>A                  p.R3539H        26.1     209/116660 = 0.002   181/64324 = 0.003
  *ZC3H3*          Chr8:144557667G\>A              NM_015117.2:c.1804C\>T                   p.R602C         25.9        2/108464 = 0         1/60294 = 0
  *EGLN2*          Chr19:41306234C\>T              NM_053046.3:c.-234-10C\>T                                6.44                         
  *EIF3J*          Chr15:44829516C\>T              NM_003758.3:c.44-6C\>T                                   12.26                        
  *HLA-DQA2*       Chr6:32714664T\>TTA             NM_020056.4:c.\*326\_\*327insTA                          1.061                        
  *LOC100507547*   Chr6:32121932C\>T               NR_037169.1:c.197+14G\>A                                 10.15                        
  *RAB4B-EGLN2*    Chr19:41306234C\>T              NR_037791.1:c.815-10C\>T                                 6.44                         
  *RANBP2*         Chr2:109384167C\>G              NM_006267.4:c.7172C\>G                   p.T2391S        11.87       5/118310 = 0         3/64908 = 0
  *RANBP2*         Chr2:109345582T\>A              NM_006267.4:c.73-6T\>A                                   12.74    453/106370 = 0.004   342/58144 = 0.006
  *ZBTB12*         Chr6:31869122G\>A               NM_181842.2:c.-20-20C\>T                                 13.36    1349/99042 = 0.014   1087/55700 = 0.02

Total list of variants from the exome analysis that filters exome sequencing results by mode of inheritance, segregation with disease, population frequency (ExAC \[Exome Aggregration Consortium\], ESP6500, UDP \[Undiagnosed Diseases Program\] founders cohort), coding effects, and location (exonic, intronic, near splice). CADD (Combined Annotation-Dependent Depletion) (v1.3) scores the deleteriousness of single-nucleotide variants as well as insertion/deletions variants in the human genome.

HGVS, Human Genome Variation Society; cDNA, complementary DNA.

Functional Analysis of Mutant Transporter {#s2c}
-----------------------------------------

To begin investigating the NKCC1 mutation, genomic DNA from the patient was used to polymerase chain reaction (PCR)-amplify and clone a fragment from the *SLC12A2* gene containing exon 22. Sequencing of randomly picked clones revealed both wild-type and mutant alleles, consistent with the heterozygous nature of her mutation. We thus confirmed that the patient carries an 11-bp deletion in exon 22, leading to the introduction of a premature stop codon and truncation of 200 amino acids of the cytosolic carboxyl terminus ([Fig. 1](#DELPIREMCS001289F1){ref-type="fig"}A,B).

![The NKCC1-DFX mutant is nonfunctional. (*A*) Sequence of a portion of *SLC12A2* exon 22 in patient shows wild-type allele (*top*) and 11-bp deletion in mutant allele (*bottom*). Translation results in a Phe residue inserted after Asp1025 followed by two stop codons (p.Val1026Phe*fs*\*2). (*B*) Schematic representation of the topology of human NKCC1 and position of the truncation. (*C*) Oocytes injected with wild-type but not mutant NKCC1 cRNA exhibit bumetanide-sensitive K^+^ influx under isotonic and hypertonic conditions. Small bumetanide-sensitive component observed with mutant is due to native amphibian NKCC1. (*D*) Western blot analysis of oocyte lysates from wild-type and mutant NKCC1 complementary RNA (cRNA) injected oocytes. (*E*) Absence of significant dominant-negative effect of mutant NKCC1 on wild-type NKCC1 in *Xenopus laevis* oocytes. The curve represents a dose--response of K^+^ influx versus amount of wild-type NKCC1 cRNA injected. The bars represent K^+^ influx of oocytes injected with equivalent amount of mutant cotransporter cRNA. The bars represent means ± S.E.M. (*n* = 20--25 oocytes). (\*\*\*) *P* \< 0.001; n.s., nonsignificant; *P* \> 0.05, one-way ANOVA followed by Tukey\'s multiple comparison posttests, WT, wild-type.](DelpireMCS001289_F1){#DELPIREMCS001289F1}

To assess the functionality of the mutant transporter (which we call NKCC1-DFX, as it terminates with an aspartic acid D followed by a phenylalanine F and a stop codon X), we injected groups of *Xenopus laevis* oocytes with NKCC1 (positive control) or NKCC1-DFX cRNAs. We then performed K^+^-influx measurements under isotonic (200 mOsM) or hypertonic (270 mOsM) conditions in the presence or absence of 20 µM bumetanide. As seen in [Figure 1](#DELPIREMCS001289F1){ref-type="fig"}C, we observed a sizable bumetanide-sensitive K^+^ influx with wild-type cotransporter under isosmotic conditions that was significantly enhanced under hypertonic conditions. In contrast, we observed minimal bumetanide-sensitive K^+^ influx with NKCC1-DFX under both osmolarities. The very small bumetanide-sensitive component detected with NKCC1-DFX is due to native *Xenopus* NKCC1 ([@DELPIREMCS001289C24]).

The absence of cotransport function could be due to absence of expression of the mutant cotransporter. To address this possibility, we introduced a C-MYC epitope tag to the extreme amino-terminal tail of both wild-type and mutant cotransporters. As seen in Supplemental Figure S3, addition of the C-MYC tag did not alter the K^+^ influx of wild-type NKCC1 under isotonic or hypertonic conditions. Western blot analysis of oocyte lysates expressing wild-type NKCC1 ([Fig. 1](#DELPIREMCS001289F1){ref-type="fig"}D) revealed the presence of a major band between 100 and 150 kDa, representing the nonglycosylated form of the cotransporter, a second band slightly more than 150 kDa, corresponding to glycosylated transporter, and a third band of higher molecular size, corresponding to a cotransporter dimer ([@DELPIREMCS001289C33]). In contrast, lysates of oocytes injected with NKCC1-DFX cRNA revealed one major band corresponding to the dimer (or misfolded aggregate) and barely detectable glycosylated and core proteins. The three bands migrate at smaller molecular sizes, due to protein truncation ([Fig. 1](#DELPIREMCS001289F1){ref-type="fig"}D).

As demonstrated in [Figure 1](#DELPIREMCS001289F1){ref-type="fig"}A, the patient carries a normal allele from which full-length NKCC1 is expressed. To determine whether the mutant allele exerts any dominant-negative effect on wild-type cotransporter, we first injected oocytes with increasing amounts of wild-type NKCC1 cRNA. As seen in [Figure 1](#DELPIREMCS001289F1){ref-type="fig"}E (curve), increasing amounts of cRNA resulted in increasing K^+^ influx with signal saturation observed above 8 ng cRNA. We then coinjected 1 or 2 ng NKCC1-DFX alongside wild-type NKCC1 and observed similar levels of K^+^ influx compared with wild-type NKCC1 alone, indicating no significant dominant-negative effect.

K^+^ transport was next examined in fibroblasts from the patient using ^86^Rb as a tracer in the presence or absence of transport inhibitors ([Fig. 2](#DELPIREMCS001289F2){ref-type="fig"}A). The identity of the fibroblasts was verified using PCR and sequencing of exon 22 from genomic DNA isolated from the cells (Supplemental Fig. S4). Ouabain (an inhibitor of the Na^+^/K^+^-pump) and bumetanide (a NKCC-specific inhibitor) reduced K^+^ transport in the patient fibroblasts by 50% and 41%, respectively. When combined, the drugs resulted in 86% reduction in K^+^ influx, indicating that the wild-type allele of NKCC1 in the patient\'s fibroblasts is functional. When compared with control healthy human fibroblasts, obtained from the Vanderbilt UDP program, some significant differences were observed. First, the overall level of K^+^ influx was reduced; second, the NKCC1-mediated influx was smaller than the pump-mediated influx; and third, under hypertonic conditions, no bumetanide-sensitive uptake could be detected ([Fig. 2](#DELPIREMCS001289F2){ref-type="fig"}B). Note that no activation of K^+^ influx was observed when exposing human fibroblasts to hypertonic conditions, a stimulus that typically leads to activation of NKCC1 ([@DELPIREMCS001289C23]). Altogether, our preliminary studies indicate that a functional NKCC1 is present, albeit to a lower level, in the patient\'s fibroblasts. The transporter behaves uncharacteristically under hypertonic conditions, as it loses its sensitivity to bumetanide.

![The behavior of the NKCC1-DFX mutant in human cells. (*A*) Characterization of major K^+^ influx pathways in fibroblasts from patient. Flux was measured in control (cnt) conditions or the absence of inhibitors, in the presence of 1 mM ouabain (ou) to inhibit the Na^+^/K^+^ pump, in the presence of 20 µM bumetanide (bu) to inhibit NKCC1, and in the presence of both inhibitors (ou + bu). (\*\*\*) *P* \< 0.001; (\*) *P* \< 0.05, one-way ANOVA followed by Tukey\'s multiple comparison posttests. (*B*) Similar experiment performed under isosmotic (310 mOsM) and hyperosmotic (385 mOsM) conditions in fibroblasts from UDP_2780 patient compared with control human fibroblasts. Bars represent means ± S.E.M (*n* = 3 dishes). (\*\*\*) *P* \< 0.001, (\*\*) *P* \< 0.01, (\*) *P* \< 0.05, n.s., nonsignificant; *P* \> 0.05, one-way ANOVA followed by Tukey\'s multiple comparison posttests. (*C*) Fluorescence images of HeLa cells transfected with tdTomato-NKCC1 (red) and EGFP-NKCC1-DFX (green). Images captured at three consecutive *Z*-sections with confocal microscopy reveals colocalization at the plasma membrane. Scale bar, 10 µm.](DelpireMCS001289_F2){#DELPIREMCS001289F2}

To assess the presence of the mutant NKCC1-DFX at the plasma membrane, we cotransfected HeLa cells with tdTomato-NKCC1 and EGFP-NKCC1-DFX cDNA constructs and imaged the cells by confocal microscopy. As seen in [Figure 2](#DELPIREMCS001289F2){ref-type="fig"}C, the two cotransporters colocalize at the plasma membrane of HeLa cells. This observation is significant because transporters with mutations in a conserved hydrophobic tetrad near the end of the carboxyl-terminal tail are unable to traffic properly to the plasma membrane ([@DELPIREMCS001289C142]). Transporters without proper carboxy-terminal signals will not traffic from the endoplasmic reticulum to the golgi. The fact that both mutant and wild-type NKCC1 transporters are found at the cell surface in a cotransfection experiment suggests that a wild-type monomer with proper trafficking signals is able to carry a mutant monomer to the cell surface. These data, confirmed by a biotinylation experiment (Supplemental Fig. S5), are consistent with our observation that the mutant transporter facilitates (or stabilizes) the formation of dimers.

DISCUSSION {#s3}
==========

At this point, we cannot establish causality between the 11-bp deletion in exon 22 of *SLC12A2* and the clinical presentation of the patient, as this is based on one individual. Note that several frameshift and stop-gained mutations in human NKCC1 are listed in the Ensembl and Exome Aggregation Consortium (ExAC) databases (data summarized in [Fig. 3](#DELPIREMCS001289F3){ref-type="fig"}). Although none of these mutations has been described in the literature, two of these individuals carrying premature stop codons (06-ST and 07-ST in [Fig. 3](#DELPIREMCS001289F3){ref-type="fig"}) were from the 1000 Genomes Project ([@DELPIREMCS001289C11]), which consisted of donors that were more than 18 years of age and classified as healthy at the time of DNA collection. This observation indicates that inactivation of one allele alone is unlikely sufficient to account for the patient\'s condition. This agrees with knockout *Slc12a2* (NKCC1) mice, which exhibit little to no overt phenotype as heterozygotes but demonstrate strong phenotypes as homozygotes ([@DELPIREMCS001289C14]; [@DELPIREMCS001289C17]; [@DELPIREMCS001289C21]). The patient does not suffer from the inner ear deficit that characterizes the homozygous NKCC1 knockout mouse ([@DELPIREMCS001289C14]; [@DELPIREMCS001289C17]; [@DELPIREMCS001289C21]), but she demonstrates the low blood pressure and gastrointestinal function deficits reminiscent of the null mice ([@DELPIREMCS001289C21]; [@DELPIREMCS001289C63]; [@DELPIREMCS001289C25]). In fact, the common gastrointestinal deficit is interesting in light of a recent report showing up-regulation of digestive enzymes produced by the exocrine pancreas of the NKCC1 knockout mouse, possibly as a way to compensate for reduced intestinal function ([@DELPIREMCS001289C6]).

![Additional SLC12A2 frameshift and stop codon variants in human population. The Ensembl genome browser database (species/gene/transcript/exons) color lists a large number of variants for each human gene, and we identified 13 unique variations leading to NKCC1 truncation. The majority of these mutations are also reported in the ExAC database (<http://exac.broadinstitute.org/>). These variants are labeled 1--13, and their position in the protein is indicated by arrows. The location of the NKCC1-DFX mutation is shown by the red arrow. The 12 transmembrane domains are designated by alternate black and gray boxes crossing the plasma membrane (blue). The location of the exons is indicated above the protein with size of introns proportionally drawn as vertical lines. DNA and amino acid sequence of the 13 variants are listed under the (1) Ensembl database and/or (2) ExAC database.](DelpireMCS001289_F3){#DELPIREMCS001289F3}

Because of metabolic issues, the patient underwent muscle and liver biopsies to investigate possible mitochondrial dysfunction. Most of her tests fell within normal range, except for increased mitochondrial DNA copy number, elevated muscle glycogen content, and increased levels of coenzyme Q10. Increased mtDNA copy number could indicate a feedback mechanism to compensate for defects in mitochondrial respiratory function. However, all enzymes measured associated with the complexes of the respiratory chain were normal. The exception was for coQ10 levels, which were significantly increased. CoQ10 is a cofactor that passes electrons between mitochondrial complexes and thus constitutes a key component of mitochondrial respiration. Increased coQ10 levels could reflect an overall increase in the number of mitochondria or an attempt to increase efficiency of the respiratory chain. In light of the otherwise normal levels of all other enzymes, it is unclear whether mitochondrial respiration and production of ATP is affected in the patient. Reduced mitochondrial respiration could explain why glycogen (energy storage) is increased in both liver and muscle. To date there is no known link between NKCC1-mediated transport and mitochondrial function. However, one could conceive that disturbed intracellular Na^+^ levels could affect intramitochondrial Ca^2+^ levels and in turn affect the respiratory chain.

The fact that no humans with complete loss of function of NKCC1 (NKCC1 knockouts) have been identified suggests intolerance to functional variation, at least in the homozygous state. If the NKCC1 mutation truly contributes to the patient\'s condition, why would some individuals with one deficient allele be affected and others would not? It is possible that additional environmental or genetic conditions that are particular to the patient have contributed to the development of the disease. Alternatively, it is also possible that this specific NKCC1 mutant protein could be expressed, whereas other mutations in the gene result in unstable transcripts or proteins. Expression of the mutant protein would then lead to deleterious effects on ion transport or cell metabolism. We found that the mutant protein is translated, at least in heterologous expression systems, and is trafficked alongside the wild-type cotransporter to the plasma membrane (seen in [Fig. 2](#DELPIREMCS001289F2){ref-type="fig"}C). In addition, we found a greater amount of protein expression, possibly indicative of a dimer, in both mutant NKCC1-injected oocytes ([Fig. 1](#DELPIREMCS001289F1){ref-type="fig"}D) and patient fibroblasts (Supplemental Fig. S4). Because the functional unit of NKCC1 is a homodimer ([@DELPIREMCS001289C42]), and the carboxy-terminal tail is involved in the formation of dimers ([@DELPIREMCS001289C51]), we propose that the mutant transporter is trafficked to the plasma membrane only when complexed with a wild-type monomer, thereby affecting the regulation of the transporter at the cell surface. Because the K^+^ transport did not respond to bumetanide under hypertonic conditions in the patient\'s fibroblasts, this indicates transport dysregulation. The bumetanide-insensitivity of mutant NKCC1 under hypertonicity is puzzling and should be pursued as it is likely to provide useful information about the biology of the cotransporter. This observation was unexpected because bumetanide is thought to interact with the cotransporter within an extracellular gate that includes residues lining transmembrane domain 3 ([@DELPIREMCS001289C54]). Thus, our data would suggest that large changes in the cytosolic carboxy-terminal portion of the cotransporter might affect the conformation of the membrane portion of the cotransporter enough to possibly occlude the bumetanide binding site. Although the hypertonic treatment is nonphysiological, it is a test that is commonly used to assess the ability of the transporter to be activated by a series of regulatory kinases that modulate NKCC1 function. Thus, the function of NKCC1 might be more affected in some cells than others. Although we did not see a very significant reduction in cotransporter function in the patient\'s fibroblasts, only subtle deficits in regulation, cotransporter function may be affected in other cell types. Note that the truncation in NKCC1-DFX occurs downstream of a signal sequence within exon 21 that targets the transporter to the basolateral membrane of epithelial cells ([@DELPIREMCS001289C9]). This sequence is absent in NKCC2, a cotransporter expressed on the apical membrane of the thick ascending limb of Henle in kidney ([@DELPIREMCS001289C34]; [@DELPIREMCS001289C9]). Some tissues (e.g., brain) express an isoform of *NKCC1* lacking exon 21 ([@DELPIREMCS001289C48]) with one possible candidate tissue being choroid plexus as it abundantly expresses NKCC1 on the apical membrane ([@DELPIREMCS001289C47]). Whether the mutant transporter is expressed and mistargeted in epithelial cells in the patient will need to be examined. The timeline of organ failure, which has accelerated in the past few years, is consistent with existing function of the cotransporter and suggests that factors such as stress on tissues or organs might be involved in the progression of the disease.

We present two major hypotheses to account for the multisystem failure in the patient. First, each tissue/organ that has failed in the patient sends sensory afferent fibers to the spinal cord. These sensory neurons have their cell bodies located in the dorsal root ganglia associated with the specific vertebrae segment(s) innervating these organs. It is known from the pioneer work of Javier Alvarez-Leefmans in amphibians that dorsal root ganglion neurons accumulate intracellular Cl^−^ in a Na^+^-, K^+^-, and furosemide-dependent manner ([@DELPIREMCS001289C3]). By using a NKCC1-specific antibody, we confirmed that the transporter involved in this accumulation is NKCC1 ([@DELPIREMCS001289C47]). We also demonstrated abnormal γ-aminobutyric acid (GABA) responses associated with a collapsed Cl^−^ gradient in DRG neurons isolated from NKCC1 knockout mice ([@DELPIREMCS001289C56]). While the role of NKCC1 in DRG neurons has been almost exclusively examined in relation to the transfer of pain signals from afferent fibers to the spinal cord ([@DELPIREMCS001289C2]; [@DELPIREMCS001289C12]), it is likely that NKCC1 fulfills a similar role in sensory innervation of tissues like the heart, lung, bladder, and intestine ([Fig. 4](#DELPIREMCS001289F4){ref-type="fig"}A). Note that, consistent with a role for NKCC1 in filtering the transfer of pain signals from the periphery to the central nervous system, we report that the patient suffers from chronic pain. Our second hypothesis, which is by no means exclusive of the first, involves smooth muscle cell contraction ([Fig. 4](#DELPIREMCS001289F4){ref-type="fig"}B). In these cells, NKCC1 also accumulates intracellular Cl^−^ above thermodynamic potential equilibrium, thereby facilitating Cl^−^ channel depolarization and triggering of Ca^2+^ channels, leading to Ca^2+^ entry and smooth muscle cell contraction ([@DELPIREMCS001289C1]; [@DELPIREMCS001289C20]; [@DELPIREMCS001289C7]). Thus, weakening of NKCC1 function in smooth muscle cells will likely affect their ability to contract affecting multiple tissues that rely on smooth muscle cell function, such as vasculature, lung, intestine, and bladder. Each of these hypotheses in relationship to the patient mutation will be addressed in future work.

![Two models are described to account for how NKCC1 function leads to multiorgan failure. (*A*) Each organ sends afferent fibers to the spinal cord to modulate autonomic function. These neurons have their cell bodies in dorsal root ganglia. Parallel arrows indicate spinal cord ascending and descending pathways. (*B*) All major organs have smooth muscle cells where NKCC1 accumulates Cl^−^ above thermodynamic potential equilibrium. Opening of Cl^−^ channels depolarizes the membrane triggering the opening of voltage-sensitive Ca^2+^ channels, Ca^2+^ entry, and contraction. NKCC1 dysfunction leads to collapse of Cl^−^ gradients in both sensory (DRG) neurons and smooth muscle cells, thereby contributing to the multiorgan pathology.](DelpireMCS001289_F4){#DELPIREMCS001289F4}

METHODS {#s4}
=======

Exome Sequencing and Analysis {#s4a}
-----------------------------

The Undiagnosed Disease Program assigned the number UDP_2780 to this patient. Whole blood was collected from patients and family members, and then DNA extraction was carried out using the Autogen FlexStar automated system following Autogen\'s standard DNA extraction method. The DNA samples were then subjected to phenol--chloroform purification and sent to the NIH Intramural Sequencing Center (NISC) for massively paralleled sequencing. Exome libraries with ∼300-bp inserts and paired-end index adapters were prepared according to Illumina\'s TruSeq DNA Sample Preparation v1 or v2 method and sequenced on a HiSeq2000 sequencer (Illumina) for 101-bp paired-end reads. The sequencing reads then were filtered for quality, and aligned to human reference genome NCBI build 37 (hg19) using in-house developed pipelines, one based on Novoalign (Novocraft Technologies), and separately a diploid aligner ([@DELPIREMCS001289C46]) run on a commercial platform (Appistry Inc.). Variants were called with HaplotypeCaller and GenotypeGVCFs ([@DELPIREMCS001289C41]; [@DELPIREMCS001289C16]; [@DELPIREMCS001289C59]). Annotations utilized SnpEff ([@DELPIREMCS001289C10]) and a combination of publicly available data sources (EXaC, ESP, 1000 Genomes). Internal cohort statistics were utilized for variant filtration. Taken together, rare, nonsynonymous, start-gain/loss, stop-gain/loss, frameshift, canonical splice site variants, and intronic variants (±20 bp) that were consistent with homozygous recessive, compound heterozygous, X-linked, or de novo dominant disease models were retained. The variants were then manually inspected using the Integrative Genomics Viewer (IGV) and checked for publicly available clinical or functional data in OMIM (Online Mendelian Inheritance in Man), HGMD (Human Gene Mutation Database), and PubMed.

*SLC12A2* Confirmation Sequencing Primers {#s4b}
-----------------------------------------

The following primers were used by the UDP program to verify the *SLC12A2* mutation---forward: 5′ GGAATTCAGCAAAAGGGACT 3′; and reverse: 5′ AACCTTACCTCCATCATCAAAAA 3′. A different primer set was used at Vanderbilt to verify the mutation in the proband\'s DNA and fibroblast samples: forward 5′ AACATTAGGAAATGATAGGAATTCAGC 3′; and reverse: 5′ TCATTTCTTACTATTCTCACAATGTCAG 3′.

NKCC Function in Fibroblasts {#s4c}
----------------------------

Fibroblasts from UDP_2780 patient and from controls were cultured in 10-cm dishes in DMEM:F12 medium containing 10% fetal bovine serum and 200 U penicillin + 200 µg/mL streptomycin and kept at 37°C under 95% air, 5% CO~2~. NKCC1 function was determined using bumetanide-sensitive K^+^ influx. Smaller dishes (35-mm) were coated with 1 mL poly-[l]{.smallcaps}-Lysine (0.1 mg/mL) overnight in the 37°C incubator. The next day, the dishes were washed twice with 1 mL sterile water and 2 mL of a high-density suspension of fibroblasts (1 × 10-cm confluent dish resuspended in 16 mL to plate 8 × 35-mm dishes) was plated in each dish. Three dishes were plated per experimental condition. Thus, all dishes were plated with equal amount of cells, minimizing variability between dishes. The cells were allowed to attach for 2 h in complete culture medium, at 37°C under 95% air, 5% CO~2~. For the flux, culture medium was aspirated from triplicate dishes and replaced with 1 mL isosmotic saline (140 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, 2 mM glucose, 5 mM HEPES---pH 7.4, 310 mOsM) or hypertonic saline (isotonic + 75 mM sucrose, 385 mOsM) for a 15 min preincubation. The preincubation solution was aspirated prior to the addition of an identical saline containing 1 mCi/mL ^86^Rb in the absence or presence of 1 mM ouabain and 20 µM bumetanide. After 15 min uptake, the solution was aspirated and the dishes washed three times with ice-cold saline. Conditions were staggered every 2 min, allowing manipulation of solutions. Dishes were kept dry until all dishes had been fluxed. At the end of the ^86^Rb uptake, 500 µL NaOH was added per dish for 1 h at RT under gentle shaking, followed by addition of 250 µL acetic acid (glacial). Samples of 300 µL and 30 µL were used for β-scintillation counting and protein assay (Bio-Rad), respectively. Influx was expressed in picomoles K^+^ per milligram protein per minute.

Fluorescence Microscopy {#s4d}
-----------------------

HeLa cells plated onto glass-bottom microwell 35-mm dishes (MatTek) were transfected with 2 µg each cDNA encoding tdTomato-fused wild-type NKCC1, EGFP-fused mutant NKCC1-DFX, and 12 µL FuGene 6.0 (ratio DNA:Fugene = 1:3; Roche Applied Science). Two days posttransfection, the cells were imaged on a Zeiss LSM 710 confocal microscope. Images were captured using a 63× oil objective (numerical aperture, 1.4) in the green fluorescent protein (GFP) (488 nm) or tdTomato (565 nm) channel using a Zeiss laser scanning LSM 710 META inverted confocal microscope.

Creation of the Mouse Mutant NKCC1 cDNA {#s4e}
---------------------------------------

We started from the cDNA encoding full-length wild-type mouse NKCC1 inserted into pBF ([@DELPIREMCS001289C13]), a vector that contains 5′- and 3′-untranslated regions from the *Xenopus* β-globin gene. Overall, mouse NKCC1 is highly conserved at the protein level (94% identity--96% homology with human NKCC1). We took advantage of a unique NheI site located 40-bp upstream of the 11-bp deletion and a unique XhoI site located after the stop codon to eliminate a 606-bp coding fragment (202 amino acids). The coding fragment was replaced with an adaptor made of two complementary oligonucleotides: forward 5′ CTAGCACACAGTTTCAGAAAAAACAAGGGAAGAATACTATAGATTTTTGAC 3′ and reverse 5′ TCGAGTCAAAAATCTATAGTATTCTTCCCTTGTTTTTTCTGAAACTGTGTG 3′. The adapter restores some 15 amino acids and adds a novel phenylalanine residue before a stop codon to mimic the patient\'s mutation. The mutant clone was sequenced to verify proper insertion of the adapter. To create c-myc-tagged constructs, we started from an EGFP-NKCC1 fusion construct ([@DELPIREMCS001289C24]) and replaced the open reading frame of EGFP by using EcoRI and BglII and ligating an adaptor made of two complementary oligonucleotides encoding the C-MYC epitope: EQKLISEEDL. The DFX mutation was then added as described above.

*Xenopus laevis* Oocytes {#s4f}
------------------------

Oocyte-positive *Xenopus laevis* female frogs were maintained in static aquaria as previously described ([@DELPIREMCS001289C15]). For surgery, frogs were anesthetized with buffered tricaine (1.7 g/L + 3.4 g/L Na-bicarbonate), placed on a wet stack of paper placed on ice, and a small 4- to 6-mm incision was made on the lower abdomen by using a disposable sterile scalpel (Feather \#11; Fisher Scientific). Ovarian lobes were externalized with sterile curved forceps, removed with sharp scissors, and placed in a 10-cm plastic culture dish containing divalent-free ND96 (96 mM NaCl, 4 mM KCl, HEPES 5 mM, pH 7.4---185 mOsM).The incision was sutured with three to four stitches by using 4--0 monofilament nylon surgical suture (DemeTech; 18-mm needle, three-eighth circle, reverse cutting). After the frogs recovered from anesthesia in shallow water, they were returned to their housing and recovered for a minimum of 8 wk. Oocytes (stages V--VI; *n* = 20--25) were defolliculated by 4 × 90-min treatments (vigorous shaking at 4°C) with 5 mL divalent-free ND96 containing 9.5 mg/mL collagenase D with washes between treatments. After the final wash, oocytes were placed in modified L15 (250 mL Leibovitz L15 Ringer \[Invitrogen\], 200 mL deionized water, 952 mg HEPES \[acid form\], and 400 µL of 50 mg/mL gentamycin \[Invitrogen\]; pH 7.0; 195--200 mOsM), filtered on 0.22 µm cellulose acetate membrane and allowed to recover overnight in a 16°C incubator.

cRNA Transcription and Injection {#s4g}
--------------------------------

cDNA clones inserted in pBF were linearized with the restriction enzyme MluI and linearized DNA (2.5 µg) was transcribed into cRNA using the mMessage mMachine SP6 transcription kit (Ambion). cRNA quality was verified by gel electrophoresis (1% agarose, 0.693% formaldehyde) and quantitated by measurement of absorbance at 260, 280, and 320 nm. The day after isolation, oocytes were injected with 50 nL water or cRNA mixture (15 ng cRNA or as indicated) by using a 10-µL digital microdispenser (Drummond Scientific) fitted with sterile pulled glass capillary tubes.

Western Blot Analysis {#s4h}
---------------------

Groups of 10 oocytes injected with C-MYC-NKCC1 or C-MYC-NKCC1-DFX were placed in the bottom of an Eppendorff tube and excess saline was removed. Lysis solution (200 µL or 20 µL per oocyte) was added to the tube and oocytes were broken by vigorous pipetting through a 200-µL pipet tip. The lysis solution contained 100 mM NaCl, 50 mM TrisCl pH 7.6, 20 mM EDTA, 1% Triton X-100, 0.1 sodium dodecyl sulfate (SDS), and protease inhibitor (Roche). After 30 min incubation on ice, the tubes were centrifuged at 14,000 rpm for 20 min at 4°C and the supernatant was passed through a minicolumn to capture oocyte lipids. Equal volume (20 µL) lysate was subjected to 6% SDS-polyacrylamide gel electrophoresis (PAGE) and the gel was transferred to a polyvinylidene fluoride (PVDF) membrane (ThermoFisher Scientific). The membrane was probed with mouse monoclonal anti-C-MYC (clone 9E10; ThermoFisher Scientific), followed by horseradish peroxidase (HRP)-conjugated secondary anti-mouse antibody (Jackson ImmunoResearch), and revealed using enhanced chemiluminescence (PerkinElmer).

K^+^ Influx Measurements in Oocytes {#s4i}
-----------------------------------

Unidirectional ^86^Rb uptake was measured in groups of 20 to 25 oocytes. Oocytes placed in a 35-mm dish were washed once with 3 mL isosmotic saline (96 mM NaCl, 4 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, 5 mM HEPES; pH 7.4) and preincubated for 15 min in 1 mL isosmotic saline containing 1 mM ouabain (to inhibit K^+^ uptake through the Na^+^/K^+^ pump). The solution was then aspirated and replaced with 1 mL isosmotic or hypertonic (+70 mM sucrose) flux solution containing 5 µCi ^86^Rb. Two 5-µL aliquots of uptake solution were taken at the beginning of each ^86^Rb-uptake to be used as standards. After 1 h, the radioactive solution was aspirated, and the oocytes were washed four times with 3 mL ice-cold solution. Oocytes were transferred into individual glass vials, lysed for 1 h with 200 µL 0.25 N NaOH, and neutralized with 100 µL glacial acetic acid. ^86^Rb tracer activity was measured by β-scintillation. K^+^ influx was calculated from counts in oocytes and standards and expressed in nanomoles per oocyte per hour.

Statistical Analyses {#s4j}
--------------------

One-way ANOVA (GraphPad Prism version 7.0, GraphPad Software, Inc) followed by Tukey\'s multiple comparisons test was used to assess statistical significance among groups in K^+^ flux data. We considered *P* \< 0.05 to be statistically significant.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The patient genomic variants were deposited in the Database of Genotypes and Phenotypes (dbGaP) (<http://www.ncbi.nlm.nih.gov/gap>) under accession number phs000721.v1.p1, in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession number SCV000328200, and in the PhenomeCentral database (<https://www.phenomecentral.org/>) under accession number P0003119.
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